Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 15 tags : Therapy save search
Competitive Generic Therapy Approvals
Published: 2021-03-15 (Crawled : 00:00) - fda.gov
ANIP S | $65.43 -1.07% -1.17% 83K
|
Health Technology
|
| O: 0.12%
H: 2.78%
C: 1.95%
therapy approval
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
SRPT | $124.25 6.09% 5.75% 1.5M
|
Health Technology
|
| O: 0.06%
H: 0.55%
C: -0.67%
gene therapy therapy results conference gene therapies
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.36%
H: 1.12%
C: 0.96%
phase 3 trial therapy injection infections
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
BTAI | News | $2.71 -8.75% -10.0% 2.8K
|
Health Technology
|
| O: 5.93%
H: 0.01%
C: -2.14%
treatment fda dementia therapy breakthrough therapy designation
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.71%
H: 3.52%
C: -2.46%
gene therapies positive therapy gene therapy milestone
bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-03-15 (Crawled : 11:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 14K
|
Health Technology
|
| O: 1.14%
H: 2.54%
C: 1.37%
gene therapy therapy gene therapies cel
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Published: 2021-03-15 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.85%
H: 0.89%
C: 0.6%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.33%
H: 2.47%
C: 2.31%
positive therapy cancer phase 3 trial
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.